An artificially intelligent, hospital-based, closed-loop glucose control system.
In today’s hospital ICU's, controlling blood sugar is an important but incredibly labor intensive process. Nurses manually prick fingers, sampling the blood for a glucose reading. Then they take this reading to a computer, where dosing software calculates an insulin dose to be delivered over the next few hours. The nurse then has to manually enter this dose into an infusion pump. This process takes 5 minutes to complete, and since it is repeated every 1-2 hours, the nurses spend up to 2 hours per patient, per day, on glucose control efforts.
Not only is this process incredibly labor intensive, it has many potential sources for error, while only delivering mediocre results. Additionally, the body’s blood sugar is constantly changing, so while the insulin dose may have been correct at the time of administration, there is very little chance it will be correct for the entire 4-hour window. It’s like driving a car with a blindfold that you can only lift every minute!
Introducing the FUSION system will change all that, as it automatically adjusts the intravenous insulin and dextrose infusions under its control every 5-10 minutes. The safe and effective glucose control offered by FUSION can benefit all ICU patients and reduce the time that nursing staff must spend on this critical function.
Lowers Mortality Rate
After an initial calibration, FUSION is able to act autonomously to regulate the dosage and dispensing of insulin/glucose. Automation of this process reduces human error and leads to safer and more effective glucose control, which results in better clinical outcomes.
Decreases Nursing Time
Currently, ICU nurses spend between 1-2 hours a day per patient on manual glucose control. Using the FUSION system will reduce this to about 20 minutes, allowing nurses to focus on what they do best: providing stellar care and support.
By decreasing the complication rate, the FUSION system has the potential to decrease the hospital length of stay by at least 2 days, which will lead to significant cost savings.
Future of Patient Care
The FUSION platform will start with glucose control, but future iterations may have the capability to control osmolality, intravascular volume status, and blood pressure.
Closed Loop System
The FUSION system works autonomously, continually adapting to the needs of the patient with no input required by nursing staff.
Easy to Use
Just enter the patient's weight, desired control range, and concentrations of the insulin and dextrose. The rest is handled automatically.
The FUSION system automatically calculates multiple glucose measurements in real time, allowing you to analyze how well the system is performing, and determine if a change to your patient's glucose control range is necessary.
Using Artificial Intelligence to mimic the bodies natural systems has the potential to offer greater control to the attending ICU physician. Increased control and reliability should result in a better outcome for the patient.
What People Say About Us
"Intensive care unit (ICU) patients develop stress induced insulin resistance causing hyperglycemia, glucose variability and hypoglycemia. These glucose metrics are associated with increased rates of morbidity and mortality. The most efficient way to achieve glucose control at lower glucose ranges will be through use of closed loop glucose control systems (artificial pancreas). A safe, effective and reliable system, well tested in clinical trials, will be a significant benefit for all ICU patients, not just those with diabetes.
"The promise of a safe and effective closed-loop glucose control system like the FUSION system that requires minimal nursing input would be amazing, and I truly cannot wait to use it to improve patient care"
Inpatient Glucose Clinical Specialist and Educator
"A safe, effective, and reliable closed-loop glucose control system that uses both intravenous insulin and intravenous dextrose would greatly benefit the cardiothoracic patients under my care, and I look forward to its introduction to the market"
Sharing our good news
FDA Approves Expansion of First Human Study